Andrew Berens
Stock Analyst at Leerink Partners
(1.79)
# 1,943
Out of 4,412 analysts
119
Total ratings
44.88%
Success rate
-7.59%
Average return
Main Sectors:
23 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Upgrades: Outperform | $69 → $110 | $66.86 | +64.52% | 1 | Apr 1, 2024 | |
| INCY Incyte | Upgrades: Outperform | $78 | $51.68 | +50.93% | 12 | Dec 13, 2023 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $10 → $5 | $0.83 | +503.65% | 4 | Aug 15, 2023 | |
| BPMC Blueprint Medicines | Downgrades: Underperform | $48 → $43 | $93.00 | -53.76% | 16 | Jun 5, 2023 | |
| ELEV Elevation Oncology | Upgrades: Outperform | $5 → $8 | $3.62 | +120.99% | 4 | May 30, 2023 | |
| MRUS Merus | Maintains: Outperform | $35 → $48 | $45.04 | +6.57% | 5 | Apr 17, 2023 | |
| DCPH Deciphera Pharmaceuticals | Reiterates: Outperform | $30 | $14.65 | +104.78% | 8 | Feb 8, 2023 | |
| BGNE BeiGene | Maintains: Outperform | $236 → $300 | $153.58 | +95.34% | 9 | Jan 20, 2023 | |
| ZYME Zymeworks | Maintains: Market Perform | $8 → $10 | $8.26 | +21.07% | 9 | Jan 20, 2023 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $6.02 | +232.23% | 4 | Jan 5, 2023 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $37 → $28 | $12.36 | +126.54% | 3 | Dec 13, 2022 | |
| ARVN Arvinas | Maintains: Outperform | $74 → $70 | $32.37 | +116.25% | 5 | Nov 23, 2022 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $75.17 | +5.10% | 10 | Nov 14, 2022 | |
| ZNTL Zentalis Pharmaceuticals | Maintains: Outperform | $42 → $27 | $11.06 | +144.12% | 7 | Nov 10, 2022 | |
| HOOK HOOKIPA Pharma | Maintains: Outperform | $4 → $3 | $0.89 | +235.83% | 3 | Aug 11, 2022 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $33 → $37 | $31.49 | +17.50% | 8 | Aug 5, 2022 | |
| CGEM Cullinan Oncology | Maintains: Outperform | $36 → $25 | $25.30 | -1.19% | 3 | May 13, 2022 | |
| CMPX Compass Therapeutics | Maintains: Outperform | $9 → $11 | $1.45 | +658.62% | 2 | May 5, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $7.22 | - | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | n/a | $6.17 | - | 1 | Oct 14, 2021 | |
| GLUE Monte Rosa Therapeutics | Initiates: Market Perform | n/a | $5.33 | - | 1 | Oct 14, 2021 | |
| TNGX Tango Therapeutics | Initiates: Outperform | n/a | $7.44 | - | 1 | Sep 20, 2021 | |
| OCUL Ocular Therapeutix | Maintains: Equal-Weight | n/a | $4.75 | - | 2 | Jul 14, 2017 |
Nuvalent
Apr 1, 2024
Upgrades: Outperform
Price Target: $69 → $110
Current: $66.86
Upside: +64.52%
Incyte
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $51.68
Upside: +50.93%
Viracta Therapeutics
Aug 15, 2023
Maintains: Outperform
Price Target: $10 → $5
Current: $0.83
Upside: +503.65%
Blueprint Medicines
Jun 5, 2023
Downgrades: Underperform
Price Target: $48 → $43
Current: $93.00
Upside: -53.76%
Elevation Oncology
May 30, 2023
Upgrades: Outperform
Price Target: $5 → $8
Current: $3.62
Upside: +120.99%
Merus
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $45.04
Upside: +6.57%
Deciphera Pharmaceuticals
Feb 8, 2023
Reiterates: Outperform
Price Target: $30
Current: $14.65
Upside: +104.78%
BeiGene
Jan 20, 2023
Maintains: Outperform
Price Target: $236 → $300
Current: $153.58
Upside: +95.34%
Zymeworks
Jan 20, 2023
Maintains: Market Perform
Price Target: $8 → $10
Current: $8.26
Upside: +21.07%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $6.02
Upside: +232.23%
Nurix Therapeutics
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $12.36
Upside: +126.54%
Arvinas
Nov 23, 2022
Maintains: Outperform
Price Target: $74 → $70
Current: $32.37
Upside: +116.25%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $75.17
Upside: +5.10%
Zentalis Pharmaceuticals
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $11.06
Upside: +144.12%
HOOKIPA Pharma
Aug 11, 2022
Maintains: Outperform
Price Target: $4 → $3
Current: $0.89
Upside: +235.83%
Agios Pharmaceuticals
Aug 5, 2022
Maintains: Outperform
Price Target: $33 → $37
Current: $31.49
Upside: +17.50%
Cullinan Oncology
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $25.30
Upside: -1.19%
Compass Therapeutics
May 5, 2022
Maintains: Outperform
Price Target: $9 → $11
Current: $1.45
Upside: +658.62%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.22
Upside: -
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.17
Upside: -
Monte Rosa Therapeutics
Oct 14, 2021
Initiates: Market Perform
Price Target: n/a
Current: $5.33
Upside: -
Tango Therapeutics
Sep 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $7.44
Upside: -
Ocular Therapeutix
Jul 14, 2017
Maintains: Equal-Weight
Price Target: n/a
Current: $4.75
Upside: -